1
|
Park S, Kye S, Jung ME, Chae CH, Yang K, Kim S, Choi G, Lee K. Discovery of TRD‐93 as a novel
DRAK2
inhibitor. B KOREAN CHEM SOC 2023. [DOI: 10.1002/bkcs.12680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- Sangjun Park
- Bio & Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon South Korea
- Medicinal Chemistry & Pharmacology University of Science & Technology Daejeon South Korea
| | - Seungmin Kye
- Bio & Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon South Korea
- Medicinal Chemistry & Pharmacology University of Science & Technology Daejeon South Korea
| | - Myoung Eun Jung
- Bio & Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon South Korea
| | - Chong Hak Chae
- Bio & Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon South Korea
| | | | | | - Gildon Choi
- Bio & Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon South Korea
- Medicinal Chemistry & Pharmacology University of Science & Technology Daejeon South Korea
| | - Kwangho Lee
- Bio & Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon South Korea
- Medicinal Chemistry & Pharmacology University of Science & Technology Daejeon South Korea
| |
Collapse
|
2
|
Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge. Cancers (Basel) 2022; 14:cancers14081931. [PMID: 35454838 PMCID: PMC9027936 DOI: 10.3390/cancers14081931] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 04/03/2022] [Accepted: 04/05/2022] [Indexed: 12/03/2022] Open
Abstract
Simple Summary Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its current applications include the first-line setting, second-line setting, as well as the adjuvant setting. Although it represents a milestone in the context of targeted therapy, inevitably all tumors develop an acquired resistance, some mechanisms involve EGFR, others do so through alternative pathways leading to a bypass in osimertinib inhibition. It is key to understand these acquired mechanisms of resistance, both in the clinical setting, as well as in preclinical models, in order to develop and contribute to the identification of possible therapeutic strategies to overcome this acquired resistance. Abstract EGFR-mutated tumors represent a significant percentage of non-small cell lung cancer. Despite the increasing use of osimertinib, a treatment that has demonstrated an outstanding clinical benefit with a tolerable toxicity profile, EGFR tumors eventually acquire mechanisms of resistance. In the last years, multiple mechanisms of resistance have been identified; however, after progressing on osimertinib, treatment options remain bleak. In this review, we cover the most frequent alterations and potential therapeutic strategies to overcome them.
Collapse
|
3
|
Du X, Yang B, An Q, Assaraf YG, Cao X, Xia J. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation (N Y) 2021; 2:100103. [PMID: 34557754 PMCID: PMC8454558 DOI: 10.1016/j.xinn.2021.100103] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Accepted: 04/01/2021] [Indexed: 12/19/2022] Open
Abstract
The discovery that mutations in the EGFR gene are detected in up to 50% of lung adenocarcinoma patients, along with the development of highly efficacious epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), has revolutionized the treatment of this frequently occurring lung malignancy. Indeed, the clinical success of these TKIs constitutes a critical milestone in targeted cancer therapy. Three generations of EGFR-TKIs are currently approved for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). The first-generation TKIs include erlotinib, gefitinib, lapatinib, and icotinib; the second-generation ErbB family blockers include afatinib, neratinib, and dacomitinib; whereas osimertinib, approved by the FDA on 2015, is a third-generation TKI targeting EGFR harboring specific mutations. Compared with the first- and second-generation TKIs, third-generation EGFR inhibitors display a significant advantage in terms of patient survival. For example, the median overall survival in NSCLC patients receiving osimertinib reached 38.6 months. Unfortunately, however, like other targeted therapies, new EGFR mutations, as well as additional drug-resistance mechanisms emerge rapidly after treatment, posing formidable obstacles to cancer therapeutics aimed at surmounting this chemoresistance. In this review, we summarize the molecular mechanisms underlying resistance to third-generation EGFR inhibitors and the ongoing efforts to address and overcome this chemoresistance. We also discuss the current status of fourth-generation EGFR inhibitors, which are of great value in overcoming resistance to EGFR inhibitors that appear to have greater therapeutic benefits in the clinic. EGFR gene mutations are detected in about 50% of non-small cell lung cancer (NSCLC) patients worldwide The three generations of EGFR tyrosine kinase inhibitors (TKIs) are critical milestones for NSCLC patients Like other targeted therapies, new EGFR mutations and coupled drug resistances emerge rapidly after TKI treatment, posing formidable obstacles to cancer management The investigational fourth-generation EGFR inhibitors are of great promise, through a number of novel mechanisms, in overcoming these resistances after third-generation TKI treatment, and will bring more benefits to NSCLC patients
Collapse
Affiliation(s)
- Xiaojing Du
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.,Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.,Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai 201199, China
| | - Biwei Yang
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.,Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - Quanlin An
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - Yehuda G Assaraf
- The Fred Wyszkowski Cancer Research Lab, Department of Biology, Technion-Israel Institute of Technology, Haifa 3200000, Israel
| | - Xin Cao
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - Jinglin Xia
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.,Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.,Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai 201199, China.,The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| |
Collapse
|
5
|
Duggirala KB, Choe H, Jeon BU, Jung ME, Go A, Lim B, Park C, Yoon J, Chae CH, Cho BC, Choi G, Lee K. Identification of TRE‐130 as Reversible Inhibitor of Pan‐EGFR Mutants while Sparing EGFR Wild‐Type Activity. B KOREAN CHEM SOC 2019. [DOI: 10.1002/bkcs.11886] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Krishna Babu Duggirala
- Bio & Drug Discovery DivisionKorea Research Institute of Chemical Technology Daejeon 34114 South Korea
- Medicinal Chemistry & PharmacologyUniversity of Science & Technology Daejeon 34113 South Korea
| | - Hyeonjeong Choe
- Bio & Drug Discovery DivisionKorea Research Institute of Chemical Technology Daejeon 34114 South Korea
| | - Byeong Uk Jeon
- Bio & Drug Discovery DivisionKorea Research Institute of Chemical Technology Daejeon 34114 South Korea
| | - Myoung Eun Jung
- Bio & Drug Discovery DivisionKorea Research Institute of Chemical Technology Daejeon 34114 South Korea
| | - Areum Go
- Bio & Drug Discovery DivisionKorea Research Institute of Chemical Technology Daejeon 34114 South Korea
| | - Byungho Lim
- Bio & Drug Discovery DivisionKorea Research Institute of Chemical Technology Daejeon 34114 South Korea
| | - Chaewon Park
- Yonsei Cancer CenterYonsei University College of Medicine Seoul 03722 South Korea
| | - Jiyeun Yoon
- Yonsei Cancer CenterYonsei University College of Medicine Seoul 03722 South Korea
| | - Chong Hak Chae
- Bio & Drug Discovery DivisionKorea Research Institute of Chemical Technology Daejeon 34114 South Korea
| | - Byoung Chul Cho
- Yonsei Cancer CenterYonsei University College of Medicine Seoul 03722 South Korea
| | - Gildon Choi
- Bio & Drug Discovery DivisionKorea Research Institute of Chemical Technology Daejeon 34114 South Korea
- Medicinal Chemistry & PharmacologyUniversity of Science & Technology Daejeon 34113 South Korea
| | - Kwangho Lee
- Bio & Drug Discovery DivisionKorea Research Institute of Chemical Technology Daejeon 34114 South Korea
- Medicinal Chemistry & PharmacologyUniversity of Science & Technology Daejeon 34113 South Korea
| |
Collapse
|
6
|
Lee S, Kim J, Duggirala KB, Go A, Shin I, Cho BC, Choi G, Chae CH, Lee K. Allosteric Inhibitor TREA-0236 Containing Non-hydrolysable Quinazoline-4-one for EGFR T790M/C797S Mutants Inhibition. B KOREAN CHEM SOC 2018. [DOI: 10.1002/bkcs.11491] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Seoyoung Lee
- Bio & Drug Discovery Division; Korea Research Institute of Chemical Technology; Daejeon 34114 South Korea
- Medicinal Chemistry & Pharmacology; Korea University of Science & Technology; Daejeon 34113 South Korea
| | - Jiwon Kim
- Bio & Drug Discovery Division; Korea Research Institute of Chemical Technology; Daejeon 34114 South Korea
- Medicinal Chemistry & Pharmacology; Korea University of Science & Technology; Daejeon 34113 South Korea
| | - Krishna Babu Duggirala
- Bio & Drug Discovery Division; Korea Research Institute of Chemical Technology; Daejeon 34114 South Korea
- Medicinal Chemistry & Pharmacology; Korea University of Science & Technology; Daejeon 34113 South Korea
| | - Areum Go
- Bio & Drug Discovery Division; Korea Research Institute of Chemical Technology; Daejeon 34114 South Korea
- Medicinal Chemistry & Pharmacology; Korea University of Science & Technology; Daejeon 34113 South Korea
| | - Inji Shin
- Bio & Drug Discovery Division; Korea Research Institute of Chemical Technology; Daejeon 34114 South Korea
- Medicinal Chemistry & Pharmacology; Korea University of Science & Technology; Daejeon 34113 South Korea
| | - Byoung Chul Cho
- Yonsei Cancer Center; Yonsei University College of Medicine; Seoul 03722 South Korea
| | - Gildon Choi
- Bio & Drug Discovery Division; Korea Research Institute of Chemical Technology; Daejeon 34114 South Korea
- Medicinal Chemistry & Pharmacology; Korea University of Science & Technology; Daejeon 34113 South Korea
| | - Chong Hak Chae
- Bio & Drug Discovery Division; Korea Research Institute of Chemical Technology; Daejeon 34114 South Korea
| | - Kwangho Lee
- Bio & Drug Discovery Division; Korea Research Institute of Chemical Technology; Daejeon 34114 South Korea
- Medicinal Chemistry & Pharmacology; Korea University of Science & Technology; Daejeon 34113 South Korea
| |
Collapse
|